Briefing From The Editor -- HSIC Stock

By Chris Stiles • Sunday, December 03 17:42 • Permanent Link

Large-cap Health Care company Henry Schein has moved 4.2% so far today on a volume of 1,741,853, compared to its average of 1,074,712. In contrast, the S&P 500 index moved 1.0%.

Henry Schein trades -5.45% away from its average analyst target price of $73.55 per share. The 11 analysts following the stock have set target prices ranging from $65.0 to $82.0, and on average have given Henry Schein a rating of hold.

Anyone interested in buying HSIC should be aware of the facts below:

Henry Schein's current price is 47.4% above its Graham number of $47.17, which implies that at its current valuation it does not offer a margin of safety
Henry Schein has moved -17.0% over the last year, and the S&P 500 logged a change of 14.0%
Based on its trailing earnings per share of 3.38, Henry Schein has a trailing 12 month Price to Earnings (P/E) ratio of 20.6 while the S&P 500 average is 15.97
HSIC has a forward P/E ratio of 13.3 based on its forward 12 month price to earnings (EPS) of $5.21 per share
The company has a price to earnings growth (PEG) ratio of 1.73 — a number near or below 1 signifying that Henry Schein is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.47 compared to its sector average of 4.08
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide.
Based in Melville, the company has 24,000 full time employees and a market cap of $9.04 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.